Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 32.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,506 shares of the company's stock after selling 42,360 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.23% of Entrada Therapeutics worth $1,513,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new stake in Entrada Therapeutics in the 4th quarter valued at about $36,000. BNP Paribas Financial Markets purchased a new stake in Entrada Therapeutics in the 4th quarter valued at about $57,000. Virtus ETF Advisers LLC acquired a new position in shares of Entrada Therapeutics in the 4th quarter valued at about $68,000. AlphaQuest LLC acquired a new position in shares of Entrada Therapeutics in the 4th quarter valued at about $70,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of Entrada Therapeutics by 53,455.6% in the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock valued at $83,000 after purchasing an additional 4,811 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Tuesday, May 20th.

Entrada Therapeutics Stock Up 2.5%

Shares of NASDAQ TRDA traded up $0.20 during midday trading on Friday, hitting $8.32. The stock had a trading volume of 92,685 shares, compared to its average volume of 133,031. The company has a fifty day moving average price of $8.23 and a 200 day moving average price of $12.31. The company has a market capitalization of $315.77 million, a price-to-earnings ratio of 5.23 and a beta of -0.06. Entrada Therapeutics, Inc. has a 1-year low of $7.10 and a 1-year high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.36. The firm had revenue of $8.75 million for the quarter, compared to analyst estimates of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. On average, research analysts forecast that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.